Home » Affymax Jumps Most in 16 Months on FDA Anemia-Drug Review
Affymax Jumps Most in 16 Months on FDA Anemia-Drug Review
Affymax surged the most in the 16 months after U.S. regulators said the company’s experimental anemia medicine works as well as drugs sold by Amgen and Johnson & Johnson for chronic kidney disease.
Bloomberg
Bloomberg
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May